Seniors Denied Access to New, Lower-Priced Generic Drugs Due to Medicare Coverage Delays
The Association for Accessible Medicines (AAM) today released a white paper, “Access Denied: Why New Generics Are Not Reaching America’s Seniors.” It highlights striking new data on the treatment of generic medicines in Medicare Part D, resulting in beneficiaries paying more for their medicines even when lower-priced FDA-approved generics and biosimilars are available.
